Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02117362
Title Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Providence Health & Services
Indications

melanoma

Therapies

Ipilimumab

Belapectin

Age Groups: adult
Covered Countries USA


No variant requirements are available.